Table 2.

Suggested doses, administration routes, regimens and side effects of micronized progesterone administrated in PCOS patients [day (d), once a day (q.d.)] (*Concentrations of 17-OH P and HOMA-IR values increased and decreased, respectively, following MP administration. Progesterone and 17-OH P concentrations were significantly lower during menstrual bleeding, whereas LH concentrations were significantly decreased and HOMA-IR values increased)

Reference	Aim	Regimen and administration route	Side effect	Primary outcome
Woods et al., 2002 [49]	Induction of withdrawal bleeding	100 mg MP q.d. per os (morning) and 200 mg MP q.d. per os (before bedtime) x 7 d	Non reported	Effects on androgens
Livadas et al., 2010 [51]	Induction of withdrawal bleeding	200 mg MP q.d. per os x 7d	Non reported	Effects on hormones and glucose metabolism*
Bagis et al., 2002 [105]	Evaluation of insulin sensitivity	300 mg MP q.d. per os or 600 mg MP vaginally x 10d	Non reported	Effects on glucose metabolism, lipids and hormones
Stanosz et al., 2014 [109]	Avoid hyperplastic endometrium in PCOS patients with preinvasive endometrial cancer	50 mg MP q.d. vaginally x 6d followed by 100 mg MP q.d. vaginally x 6d, plus 17β-E2 transdermally (22 d cycle)	Non reported	Effects on hormones, lipids and endometrium